As observed with previously described pCARs (10), all CD19-specific pCAR T-cells achieved markedly enhanced tumor re-stimulation activity, maintained capacity to produce IL-2 over repeated stimulation and reduced expression of exhaustion markers, most notably PD1. This evidence concerns the gene CD19 and neoplasm.